Immune signaling proteins and immune cell surface receptors

The term Immune signaling proteins and immune cell surface receptors refers to a vast and diverse group of molecules that mediate the body's defense mechanisms (Janeway's Immunobiology, 9th ed.). This category includes membrane-bound receptors like G protein-coupled receptors, ion channels, and immune checkpoints such as PD-1 and CTLA-4, as well as secreted signaling proteins like cytokines and chemokines (PubMed: 28414333). These molecules are essential for the detection of pathogens, the activation of leukocytes, and the maintenance of self-tolerance (UniProt: Immune System Process). In clinical medicine, components of these pathways are frequently targeted to treat conditions ranging from rheumatoid arthritis to metastatic cancer (NIH: Immunotherapy). However, because this designation encompasses thousands of distinct proteins with varying structures and functions, it does not represent a single, valid therapeutic target for drug development or regulatory purposes. Consequently, it is classified as an incorrect target entry due to being overly broad and lacking the specificity required for pharmacological characterization. Effective drug discovery requires the identification of specific molecular entities, such as Janus kinase 1 or Interleukin-6 receptor, rather than broad functional classes. This entry serves as a high-level classification rather than a discrete point of therapeutic intervention.

Other names

Immune receptorsImmune system proteinsLeukocyte surface antigensImmunomodulatory proteinsImmune signaling molecules

Varies significantly across the class; includes inhibition of signaling cascades, receptor blockade, and immune checkpoint modulation.